Table 2 –
Estimated changes from baseline in the circulating numbers of total leukocytes, platelets, and erythrocytes as well as the absolute and relative counts of the leukocyte subtypes for testosterone dose groups in the 5aR trial.
| Testosterone Enanthate Dose Group | Dose-Effect | ||||
|---|---|---|---|---|---|
| 50mg | 125mg | 300mg | 600mg | P-Value | |
| Erythrocyte count, 106 cells/μL | −0.07 (−0.16, 0.02) | 0.19 (0.09, 0.29) | 0.35 (0.26, 0.45) | 0.32 (0.23, 0.40) | <0.001 |
| Platelets, 103cells/μL | −7.3 (−16.3, 1.7) | 8.4 (−1.6, 18.4) | 8.7 (−0.6, 18.1) | 8.9 (0.5, 17.4) | 0.033 |
| Leukocyte count, 103cells/μL | 0.04 (−0.33, 0.41) | 0.49 (0.07, 0.91) | 1.23 (0.83, 1.62) | 1.28 (0.92, 1.64) | <0.001 |
| Neutrophils count, cells/μL | 65.1 (−293.6, 423.9) | 436.1 (27.7, 844.4) | 1177.2 (790.1, 1564.4) | 1192.2 (849.2, 1535.1) | <0.001 |
| Lymphocyte count, cells/μL | −7.89 (−123.9, 108.1) | −14.4 (−146.1, 117.3) | 38.7 (−86.0, 163.5) | −83.7 (−194.8, 27.3) | 0.53 |
| Monocyte count, cells/μL | −20.2 (−52.7, 12.4) | 24.5 (−12.9, 61.9) | 90.6 (55.5, 125.8) | 143.9 (112.8, 175.0) | <0.001 |
| Eosinophil count, cells/μL | 0.67 (−30.3, 31.7) | 39.1 (4.1, 74.1) | −2.70 (−36.3, 30.8) | 3.1 (−26.5, 32.8) | 0.29 |
| Basophil count, cells/μL | −2.61 (−8.95, 3.73) | 0.82 (−6.48, 8.13) | 1.58 (−5.21, 8.38) | −0.36 (−6.40, 5.67) | 0.82 |
| Neutrophil, % | 0.03 (−2.09, 2.14) | 1.61 (−0.79, 4.00) | 5.98 (3.70, 8.25) | 6.79 (4.77, 8.80) | <0.001 |
| Lymphocyte, % | 0.65 (−1.15, 2.44) | −2.06 (−4.10, −0.03) | −5.21 (−7.14, −3.27) | −6.71 (−8.43, −4.99) | <0.001 |
| Monocyte, % | −0.35 (−0.82, 0.12) | −0.14 (−0.68, 0.41) | −0.19 (−0.70, 0.32) | 0.70 (0.25, 1.15) | 0.008 |
| Eosinophil, % | 0.03 (−0.44, 0.49) | 0.48 (−0.04, 1.00) | −0.56 (−1.06, −0.06) | −0.47 (−0.91, −0.03) | 0.014 |
| Basophil, % | −0.05 (−0.15, 0.05) | 0.003 (−0.11, 0.12) | −0.05 (−0.16, 0.05) | −0.07 (−0.16, 0.03) | 0.81 |
Data are expressed as estimated change from baseline (95% Confidence Intervals). P values, derived from the mixed-effects regression model with repeated measures framework for testosterone dose-effect, are also shown.